June 09, 2026 02:06 ET | Source: Harness Therapeutics Grant awarded through the Parkinson’s Disease Therapeutics Pipeline Program to support advancement of Harness’ new programme targeting GCase and LIMP2 for Parkinson’s disease Two-year programme expands Harness’ neurodegenerative disease pipeline, leveraging proprietary MISBA® platform Cambridge, UK, 9 June 2026: Harness Therapeutics (‘Harness’), a biotechnology company unlocking […] The post…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.